EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for the Treatment of Wet AMD

NEXT STORY
Medivolve Announces Investment Into Marvel Diagnostics and Its Non-Invasive Exhaled Breath Diagnostic Technology
PREV STORY
Sharps Compliance Reports Fiscal 2021 Second Quarter Results
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

TiGenix to present at the 7th TERMIS-EU Conference in Davos, Switzerland

PRESS RELEASE TiGenix to present at the 7th TERMIS-EU Conference in Davos, Switzerland Leuven ...

author_avatar
NASDAQ Market News

Leap Therapeutics Provides DKN-01 Program Update and Announces Scientific Presentations at AACR Annual Meeting

CAMBRIDGE, Mass., March 14, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology ...

author_avatar
NASDAQ Market News

Rafael Pharmaceuticals Announces Initiation of Phase II Trial of CPI-613 in Combination with Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer

Newark, NJ, Jan. 09, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in ...

author_avatar
NASDAQ Market News